Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer’s disease, a recent study from neuroscientists at the University of South Florida shows. Findings from the experiments, using a cellular model of Alzheimer’s disease, were reported online in the Journal of Alzheimer’s Disease.

Researchers from the USF Health Byrd Alzheimer’s Institute showed that extremely low doses of THC reduce the production of amyloid beta, found in a soluble form in most aging brains, and prevent abnormal accumulation of this protein — a process considered one of the pathological hallmarks evident early in the memory-robbing disease. These low concentrations of THC also selectively enhanced mitochondrial function, which is needed to help supply energy, transmit signals, and maintain a healthy brain.

“THC is known to be a potent antioxidant with neuroprotective properties, but this is the first report that the compound directly affects Alzheimer’s disease pathology by decreasing amyloid beta levels, inhibiting its aggregation, and enhancing mitochondrial function,” said study lead author Chuanhai Cao, PhD and a neuroscientist at the Byrd Alzheimer’s Institute and the USF College of Pharmacy.

“Decreased levels of amyloid beta means less aggregation, which may protect against the progression of Alzheimer’s disease. Since THC is a natural and relatively safe amyloid inhibitor, THC or its analogs may help us develop an effective treatment in the future.”

The researchers point out that at the low doses studied, the therapeutic benefits of THC appear to prevail over the associated risks of THC toxicity and memory impairment. Neel Nabar, a study co-author and MD/PhD candidate, recognized the rapidly changing political climate surrounding the debate over medical marijuana.

“This study indicates that THC and THC-related compounds may be of therapeutic value in Alzheimer’s disease,” Nabar said. “These findings may lead to the development of related compounds that are safe, legal, and useful in the treatment of Alzheimer’s disease.”

The body’s own system of cannabinoid receptors interacts with naturally-occurring cannabinoid molecules, and these molecules function similarly to the THC isolated from the cannabis (marijuana) plant.

“The dose and target population are critically important for any drug, so careful monitoring and control of drug levels in the blood and system are very important for therapeutic use, especially for a compound such as THC,” Dr. Cao said.

The medical term for prion disease is transmissible spongiform encephalopathy, which includes ALS, Alzheimer’s disease, Parkinson’s disease, Creutzfeldt-Jakob disease, mad cow disease, chronic wasting disease.

Despite the smoke and mirrors, the major difference between all of these forms of neurodegenerative disease is the species under attack by infectious prions and the region of the brain that is under attack (first symptom). The primary difference between Alzheimer’s disease and Parkinson’s disease, for example, is the region of the brain that is under attack by the pathological protein. Learn how to prevent and treat all forms of prion disease.

There are proven strategies to help avert neurodegenerative disease, including nutrition, exercise and prion aversion. There is not a cure for prion disease. Preview and order the eBook now to defend yourself and your family.

The post Treat Neurodegenerative Disease With Marijuana appeared first on Neuroscience News.